NewLimit
Wesley McKeithan is a Senior Scientist at NewLimit, bringing extensive experience from roles such as Scientist II at Maze Therapeutics and Postdoctoral Scholar at University of California, San Francisco and Stanford University School of Medicine. With a background in biomedical sciences, Wesley has expertise in areas such as stem cell biology, regenerative medicine, and cardiac electrophysiology. Wesley has a PhD in Biomedical Sciences from Sanford Burnham Prebys Medical Discovery Institute Graduate School of Biomedical Sciences.
This person is not in the org chart
NewLimit
NewLimit is a biotechnology company working to radically extend human healthspan. We’re developing medicines to treat age-related diseases by reprogramming the epigenome, a new therapeutic mechanism to restore regenerative potential in aged and diseased cells. We leverage functional genomics, pooled perturbation screening, and machine learning models to unravel the biology of epigenetic aging and disease using experiments of unprecedented scale.